Taxotere docetaxel: Phase III data

Follow-up data from the international Phase III BCIRG 001/TAX 316 study in 1,491 patients showed that Taxotere based adjuvant therapy reduced the risk of relapse by 28% (p=0.001) and of death by 30% (...